2. Cytoskeleton Metabolic Enzyme/Protease Anti-infection
  3. Integrin Endogenous Metabolite Bacterial
  4. PA-IIL

PA-IIL (LecB) 是一种由铜绿假单胞菌产生的凝集素。PA-IIL 可与糖基化的 β1-整合素、含岩藻糖的糖鞘脂、岩藻糖基化/甘露糖基化的中性粒细胞糖缀合物以及预先形成的中性粒细胞胞外陷阱结合。PA-IIL 可瓦解宿主防御：通过调节中性粒细胞的杀菌活性、破坏免疫细胞的运输和招募、以及损伤上皮屏障的修复能力，为铜绿假单胞菌的感染和传播创造有利条件。PA-IIL 可用于铜绿假单胞菌感染的相关研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

PA-IIL

PA-IIL Chemical Structure

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

PA-IIL 相关抗体

Top Publications Citing Use of Products

查看 Integrin 亚型特异性产品:

查看所有亚型
αvβ1 αvβ3 αvβ5 αvβ6 αvβ8 α5β1 α1β1 α2β1 α4β1 α9β1 αIIbβ3 α4β7 αLβ2

查看 Endogenous Metabolite 亚型特异性产品:

查看所有亚型
Human Endogenous Metabolite Microbial Metabolite

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

PA-IIL (LecB) is a lectin produced by Pseudomonas aeruginosa. PA-IIL binds to glycosylated β1-integrin, fucose-containing glycosphingolipids, fucosylated/mannosylated neutrophil glycoconjugates, and pre-formed neutrophil extracellular traps. PA-IIL disrupts host defenses: it creates favorable conditions for Pseudomonas aeruginosa infection and dissemination by modulating the bactericidal activity of neutrophils, impairing the trafficking and recruitment of immune cells, and compromising the repair capacity of epithelial barriers. PA-IIL can be used in studies related to Pseudomonas aeruginosa infection[1][2][3][4].

体外研究
(In Vitro)

PA-IIL (50 μg/mL; 6-12 h) 经基底侧给药时会破坏 MDCK 细胞的上皮极性和紧密连接完整性，而顶端给药则无此效应[1]。
PA-IIL (50 μg/mL; 1-6 h + 5-20 h 洗脱) 从基底侧施加时会导致 MDCK 细胞中 β1-整合素快速内化，且该效应在 LecB 洗脱后可逆，整合素的表面定位和 TEER 会随时间恢复[1]。
PA-IIL 可特异性结合 MDCK 细胞基底外侧表面的糖基化 β1-整合素，其结合亲和力较强，可提取总 β1-整合素的 75%[1]。
PA-IIL (50 μg/mL; 10 min-6 h) 当从基底侧施加时，会导致 MDCK 细胞中 α3β1 整合素-层粘连蛋白复合物发生内吞和溶酶体降解，且该效应与 β1 整合素的激活状态无关[1]。
PA-IIL 可通过结合含岩藻糖的糖鞘脂诱导膜内陷，并在 MDCK 细胞中使这些内陷膜区域与 β1-integrins 发生交联，为整合素内化提供了一种机制[1]。
PA-IIL (5-100 μg/mL; 3-22 h) 可在体外以剂量依赖方式抑制 MDCK 细胞的上皮伤口愈合，浓度高于 50 μg/mL 时可完全阻断细胞迁移，其作用机制为诱导伤口边缘细胞的 β1-integrin 内吞并抑制板状伪足形成[1]。
PA-IIL (5 μM; 3 days) 可抑制人皮肤外植体中真皮 CD14+树突状细胞 (DC)、真皮 CD14-树突状细胞以及表皮朗格汉斯细胞的迁出，并下调真皮树突状细胞表面 CD18/ITGb2-CD11c/ITGb2 异二聚体的表达[3]。
PA-IIL (1 μg/mL; 2 h) 可与体外分离的人血液及淋巴管内皮细胞结合[3]。
PA-IIL (5 μg/mL; 17 h) 会抑制人 PBMC、淋巴细胞和单核细胞穿过人 CMEC/D3 内皮单层的迁移，增加白细胞与该单层的黏附，并破坏内皮细胞膜上 VE-cadherin 的定位[3]。
PA-IIL (5 μg/mL; 1-5 h) 可诱导人脐静脉内皮细胞 (HUVECs) 中 VE-cadherin 的时间依赖性内吞与降解、F-actin 细胞骨架重排、FAK 移位、肌球蛋白调节轻链磷酸化水平降低以及细胞运动停滞，且无细胞毒性[3]。
PA-IIL (0.015-3 μM) 可以浓度依赖的方式在 LPS 预刺激和 TNFα 预刺激的人中性粒细胞中诱导细胞内活性氧生成 (但在未预刺激或 37℃预刺激的中性粒细胞中无此作用)，在 1.5 μM 及以上浓度时具有显著活性[4]。
PA-IIL (0.015-3 μM; 30 min) 对未预刺激、37℃ 预刺激、LPS 预刺激及 TNFα 预刺激的人中性粒细胞表面的结合能力无差异，且结合呈浓度依赖性增强，该结合可被岩藻糖甲酯完全抑制[4]。
PA-IIL (1.5 μM) 可抑制未激活人中性粒细胞在接触血清调理的铜绿假单胞菌或金黄色葡萄球菌时，由吞噬作用诱导的细胞内活性氧生成[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PA-IIL 相关抗体:
体内研究
(In Vivo)

PA-IIL (12.5 µg; 皮内注射、足垫注射；间隔 18 小时给药 2 次，单次给药) 可结合小鼠皮肤及淋巴结中的淋巴管内皮细胞与血管内皮细胞，抑制树突状细胞从皮肤迁移至淋巴结的 CD4+ T 细胞区，并降低抗原特异性 CD4+ T 细胞的增殖能力，且这些效应可被 LecB 抑制剂逆转[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Prox1CreERT2 tdTomatoStop-flox [iProx-1tdT], C57BL/6J, CD45.1 [B6.SJL-Ptprca Pepcb/BoyJ], OT-II [B6.Cg-Tg(TcraTcrb)425Cbn/J], B6;129S6-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze[3]
Dosage: 12.5 µg (i.d., ear pinnae, 2 doses); 12.5 µg (i.fp., single dose)
Administration: i.d. (ear pinnae, 2 doses 18 hours apart); i.fp. (single dose)
Result: Co-localized with tdTomato+ lymphatic vessels in mouse ear skin and bound to CD31+ CLCA1+ lymphatic vessels and CD31+ CLCA1- blood vessels in draining lymph nodes, with median fluorescence intensity ~35,000 for lymphatic endothelial cells, showing significantly higher binding than saline control.
Reduced Langerhans cell numbers from ~20,000 to ~15,000, cDC1 numbers from ~10,000 to ~8,000, and cDC2 numbers in draining auricular lymph nodes despite increased total lymph node cellularity from imiquimod stimulation.
Caused BMDCs to associate with subcapsular lymphatics instead of migrating to the T cell zone, significantly reducing BMDC numbers in the T cell zone and significantly increasing numbers associated with lymphatics; this effect was reversed by co-administration of DH445.
Reduced the proportion of proliferating CD4+ T cells from ~80% to ~40% relative to control; co-administration of DH445 restored T cell proliferation to ~85% relative to control.
中文名称

绿脓杆菌凝集素
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

PA-IIL 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

PA-IILLecB绿脓杆菌凝集素IntegrinEndogenous MetaboliteBacterialdendritic cellsCMEC/D3 endothelial monolayerVE-cadherincystic fibrosisneutrophil extracellular trapsβ1-integrinHUVECsMDCK cellsPseudomonas aeruginosaneutrophilsInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
PA-IIL
目录号：
HY-NP216
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z